Over 30 pharmaceutical companies are actively developing more than 30 drugs for cutaneous T-cell lymphoma (CTCL), a rare skin-related non-Hodgkin lymphoma. Key players like Prescient Therapeutics and Innate Pharma are advancing promising therapies through various clinical trial phases, including late-stage development. Innovations focus on targeted and immunotherapies, aiming to improve treatment options despite challenges like limited patient populations and high costs. The market is expected to grow steadily as new drugs progress toward approval and commercial availability.
At its May 21, 2026 Annual General Meeting, Nexans shareholders approved all 22 board resolutions, including an 11.5% increase in dividends to €2.90 per share payable on May 27. The meeting also renewed independent board members Laura Bernardelli and...
Torque Asset Management purchased $4 million worth of Planet Fitness shares amid a significant 54% decline in the stock price during 2026. This move suggests confidence in the company's recovery potential despite the sharp drop. Investors may watch c...
Crescendo announced winners of its inaugural 2026 Customer Awards, recognizing five companies excelling in AI-powered customer experience (CX). Winners include Nothing Bundt Cakes for customer obsession, Lovepop for practical AI use, Grindr for forwa...
Lennox International Inc., a leader in energy-efficient building solutions, announced an increase in its quarterly dividend from $1.30 to $1.36 per share. The dividend will be paid on July 15, 2026, to shareholders of record as of June 30, 2026. This...
Deere & Company beat Q2 earnings estimates with EPS of $6.55 and revenue of $13.369 billion, driven by strong Small Ag and Construction & Forestry sales. However, Production & Precision Agriculture sales fell 14%, pressured by lower shipments and ris...
